TP53 and lymphoma: Overall, TFHL-PDX maintained the primary lymphoma-associated DNA methylation profile after treatment, and azacitidine administration was associated with a global loss of DNA methylation that was seemingly more pronounced in azacitidine-sensitive than resistant models, and resulted in DNA methylation changes across various regions interacting with the TP53 and belonging to various pathways.